Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
复制标题
DOI:
10.1016/j.jpba.2016.01.038
复制
发表时间:
2016-04-15
影响因子:
3.4
通讯作者:
Anderson PL
中科院分区:
文献类型:
--
作者:
Zheng JH;Rower C;McAllister K;Castillo-Mancilla J;Klein B;Meditz A;Guida LA;Kiser JJ;Bushman LR;Anderson PL
This communication describes the application of an existing intracellular methodology to the quantitation of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) from erythrocytes using dried blood spots (DBS). Concentrations were determined from a 3mm DBS punch extracted into a 70:30 methanol:water solution (lysed cellular matrix). This extraction solution was then subjected to a previously validated analytical procedure for lysed cellular matrix. Experiments for DBS validation used replicate samples from study participants to demonstrate acceptable reproducibility with spot volumes ranging from 10μL to 50μL and punch location either from the edge or center of the spot. Analysis of paired DBS with purified red blood cells showed that a 3mm DBS punch contained an average of 11.9 million cells for the observed hematocrit range of the participants (35% to 50%). Numerous stability tests were completed showing that whole blood in an EDTA vacutainer could sit for 24 hours at room temperature prior to spotting, and DBS could remain at room temperature for up to five days including shipment at ambient using 2-day delivery. DBS stability in storage was acceptable up to 18 months at −20°C or −80°C and DBS could undergo 4 Freeze/Thaw cycles. The described method was applied to HIV prophylaxis studies, demonstrating powerful associations with HIV acquisition through its ability to discriminate gradients of adherence.